Comparison of Antiplatelet Effects of Two Nitric Oxide-donating Agents, FR146801 and FK409

Yoshimi Hirasawa; Yasuko Kato; Shinichi Fukuyama; Mitsuko Ohno; Shigetaka Nishino; Masayuki Kato; Yasuhiro Kita

doi:10.1055/s-0037-1614956

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(03): 620-624
DOI: 10.1055/s-0037-1614956

Review Articles

Schattauer GmbH

Comparison of Antiplatelet Effects of Two Nitric Oxide-donating Agents, FR146801 and FK409

Autor*innen

Yoshimi Hirasawa

¹New Drug Research Laboratories
Yasuko Kato

¹New Drug Research Laboratories
Shinichi Fukuyama

²Analytical Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
Mitsuko Ohno

¹New Drug Research Laboratories
Shigetaka Nishino

¹New Drug Research Laboratories
Masayuki Kato

¹New Drug Research Laboratories
Yasuhiro Kita

¹New Drug Research Laboratories

Abstract

Summary

In the present study, we examined the antiplatelet effects of the two nitric oxide (NO)-donating agents, (±)-N -[(E)-4-ethyl-3-[(Z)hydroxyimino]-6-methyl-5-nitro-3-heptenyl]-3-pyridinecarboxamide (FR146801), a more stable analog of FK409 ((±)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide), and FK409 in in vitro and in vivo experiments. FR146801 and FK409 inhibited ADP- and collagen-induced platelet aggregation in human and rat platelet-rich plasma in a concentration-dependent manner, however, the inhibitory effect of FR146801 was weaker than that of FK409. In human washed platelets (WP), FR146801 and FK409 inhibited collagen-induced platelet aggregation in a concentration-dependent manner. The inhibitory effects of FR146801 and FK409 on platelet aggregation were closely reflected by the increase in the intraplatelet cGMP level. This intensely suggests that the antiplatelet activities of FR146801 and FK409 are due to NO-released from them. In the rat extracorporeal shunt model, FR146801 inhibited thrombus formation dose-dependently and its inhibition was significant at 10 mg/kg, p.o. FK409 suppressed thrombus formation significantly at 1.0 mg/kg, p.o., at which it induced significant hypotension, whereas FR146801 did not show any significant hypotensive effect even at 10 mg/kg, p.o. These results suggest that FR146801 has desirable antiplatelet effects both in vitro and in vivo and that its in vivo antiplatelet effect is more selective than its hypotensive effect, while FK409 does not show a selective antiplatelet effect in vivo.

Volltext

Referenzen

References
1 Hino N, Iwami M, Okamoto M, Yoshida K, Haruta H, Okuhara M, Hosoda J, Kohsaka M, Aoki H, Imanaka H. FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. I. Taxonomy, fermentation, isolation, and physio-chemical and biological characteristics. J Antibiotics 1989; 42: 1578-83.
2 Kita Y, Hirasawa Y, Maeda K, Nishio E, Yoshida K. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Eur J Pharmacol 1994; 257: 123-30.
3 Mellion BT, Ignaro LJ, Ohlstein EH, Pontecorovo EG, Hyman AL, Kadowitz PJ. Evidance for the inhibitory role of guanosine 3’,5’-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 945-55.
4 Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-7.
5 Ignarro LJ. Biological actions and properties of endotherium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1-21.
6 Hjemdahl-Monsen CE, Lewis HD, Cairns J, Chesebro JH, Fuster V. Role of antithrombotic therapy in unstable angina, myocardial infarction and sudden death. J Am Coll Cardiol 1986; 8 Suppl B 67B-75B.
7 Fuster V, Badimon L, Cohn M, Ambrose JA, Badimon JJ, Chesebro J. Insight into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-20.
8 Ferns GAA, Raines EW, Srugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-32.
9 Kita Y, Hirasawa Y, Yoshida K, Maeda K. Antiplatelet activities of FK409, a new spontaneous NO releaser. Br J Pharmacol 1994; 113: 385-8.
10 Kita Y, Ozaki R, Sakai S, Sugimoto T, Hirasawa Y, Ohtsuka M, Senoh H, Yoshida K, Maeda K. Antianginal effects of FK409, a new spontaneous NO releaser. Br J Pharmacol 1994; 113: 1137-40.
11 Kita Y, Sugimoto T, Hirasawa Y, Yoshida K, Maeda K. Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level. Br J Pharmacol 1994; 113: 5-6.
12 Seki J, Nishio M, Kato Y, Motoyama Y, Yoshida K. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis 1995; 117: 97-106.
13 Kita Y, Hirasawa Y, Fukuyama S, Ohno M, Nishino S, Kato M. Oral biological activities of spontaneous NO releasers are accounted for by NO-releasing rates and oral absorption manners. J Pharmacol Exp Ther 1996; 276: 421-5.
14 Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708-16.
15 Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1968; 168: 178-95.
16 Bell FK, O’Neill JJ, Burgison RM. Determination of the oil/water distribution coefficients of glyceryl trinitrate and two similar nitrate esters. J Pharmacol Sci 1963; 52: 637-9.
17 Umetsu T, Sanai K. Effects of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost 1987; 39: 74-83.